Evidence map›Paper›PMID 33681865›Full record

ArticleAdvanced nanobiomed research2021

Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019.

Halle Lutz, Kristen D Popowski, Phuong-Uyen C Dinh, Ke Cheng

Open access · goldAbstract read
In one paragraph

Article in Advanced nanobiomed research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Halle LutzDepartment of Molecular Biomedical Sciences North Carolina State University Raleigh NC 27607 USA.ORCID 0000-0001-6364-7627
Kristen D PopowskiDepartment of Molecular Biomedical Sciences North Carolina State University Raleigh NC 27607 USA.ORCID 0000-0002-6341-2251
Phuong-Uyen C DinhDepartment of Molecular Biomedical Sciences North Carolina State University Raleigh NC 27607 USA.ORCID 0000-0002-8969-6256
Ke ChengDepartment of Molecular Biomedical Sciences North Carolina State University Raleigh NC 27607 USA.ORCID 0000-0001-8053-7059
North Carolina State University · USUniversity of North Carolina at Chapel Hill · US

Funding

Targeted Nanoparticles for Stem Cell Redirecting and Regenerative MedicineR01HL123920 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI CHENG, KE · 2015 to 2023
$4.8M
Harnessing Platelet-Endothelial Interactions for Stem Cell DeliveryR01HL144002 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI Ke Cheng · 2019 to 2026
$4.5M
Modulating Exosome Cargos and Surfaces for Precision Heart RepairR01HL146153 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI Ke Cheng · 2019 to 2026
$4.2M
Surgical Microneedle Patch Delivery of CMMP for Heart RepairR01HL149940 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI CHENG, KE, LI, SONG · 2020 to 2023
$3.0M
Cardiac Patches Loaded with Stem Cell Factors to Treat Heart FailureR01HL147357 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI CHENG, KE · 2019 to 2022
$2.7M
Enhancing vascular delivery of stem cells and microparticlesR01HL137093 · NHLBI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI CHENG, KE · 2017 to 2020
$1.5M
NHLBI NIH HHS R01 HL123920NHLBI NIH HHS R01 HL137093NHLBI NIH HHS R01 HL144002NHLBI NIH HHS R01 HL146153NHLBI NIH HHS R01 HL147357NHLBI NIH HHS R01 HL149940
6 · The paper itself

Abstract

New infectious diseases are making themselves known as the human population grows, expands into new regions, and becomes more dense, increasing contact with each other and animal populations. Ease of travel has also increased infectious disease transmission and has now culminated into a global pandemic. The emergence of the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 has already infected over 83.7 million people and caused over 1.8 million deaths. While there have been vaccine candidates produced and supportive care implemented, the world is impatiently waiting for a commercially approved vaccine and treatment for the coronavirus disease of 2019 (COVID-19). The different vaccine types investigated for the prevention of COVID-19 all have great promise but face safety obstacles that must be first addressed. Some vaccine candidates of key interest are whole inactivated viruses, adeno-associated viruses, virus-like particles, and lipid nanoparticles. This review examines nanobiomedical techniques for combatting COVID-19 in terms of vaccines and therapeutics.

Indexed as

coronavirus diseaseexosomesnanomedicinesevere acute respiratory syndrome coronavirus 2therapeuticsvaccines

Identifiers

PMID33681865
PMCPMC7917381
OpenAlexW3115225258

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.